 REDWOOD CITY, Calif., Aug. 26, 2021 GLOBE NEWSWIRE -- Bolt Biotherapeutics, Inc. Nasdaq: BOLT, a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, and Innovent Biologics, Inc. HKEX: 01801, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate ISAC candidates. 